Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
Type:
Grant
Filed:
July 13, 2022
Date of Patent:
December 16, 2025
Assignee:
GigaMune, Inc.
Inventors:
Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio
Abstract: The present disclosure relates to a novel, engineered enveloped vector that can be used for gene delivery. The engineered enveloped vector comprises an engineered envelope comprising: (a) a viral envelope protein and optionally, (b) a non-viral membrane-bound protein. The present disclosure also provides a method of making and using the engineered enveloped vector.
Type:
Grant
Filed:
September 7, 2023
Date of Patent:
July 29, 2025
Assignee:
GigaMune, Inc.
Inventors:
David Scott Johnson, Matthew James Spindler, Robert Edgar, Yoong Wearn Lim, Taylor Weller
Abstract: Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell rectors with specificity against EBV or CMV peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against viral infections.
Type:
Grant
Filed:
September 21, 2021
Date of Patent:
August 23, 2022
Assignee:
GigaMune, Inc.
Inventors:
Matthew James Spindler, David Scott Johnson, Ayla Lynn Nelson, Ellen Kathleen Wagner, Adam Shultz Adler, Yoong Wearn Lim, Michael Asensio
Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.
Type:
Grant
Filed:
May 18, 2017
Date of Patent:
March 27, 2018
Assignee:
GigaMune, Inc.
Inventors:
David Scott Johnson, Adam Adler, Rena Mizrahi
Abstract: Disclosed herein are methods and compositions for generating a repertoire of recombinant fusion polypeptides from immune cells, and uses thereof.
Type:
Grant
Filed:
May 18, 2017
Date of Patent:
March 27, 2018
Assignee:
GigaMune, Inc.
Inventors:
David Scott Johnson, Adam Adler, Rena Mizrahi